sareum holdings plc (SAR) Details

Sareum Holdings plc, through its subsidiaries, engages in the discovery and development of therapeutic drugs for the treatment of cancer and auto-immune diseases. The company focuses on developing small molecule drug candidates for licensing to pharmaceutical and biotechnology companies. It develops research programmes based on its Sareum Kinase Inhibitor Library (SKIL) technology platform that comprises the chemistry and expertise to generate kinase inhibitors. The company’s principal drug discovery programs include the Checkpoint kinase 1 (Chk1) program for treating colon, pancreatic, and lung cancer, as well as neuroblastoma; the Aurora+FLT3 kinase program for treating acute myeloid leukaemia and colon cancer; and the Aurora+ALK kinase program for treating anaplastic large cell lymphoma, lung cancers, and childhood neuroblastomas. Its drug discovery programs also comprise the Tyrosine kinase 2 (TYK2) program for the treatment of multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn’s disease; the VEGFR-3 (FLT4) kinase program for the treatment of lung, gastric, and prostate cancers; microtubule binding agents program for various cancers; and other programs, such as FLT3, PLK1, FASN, and B-RAF for various cancer indications. The company was founded in 2003 and is headquartered in Cambridge, the United Kingdom.

sareum holdings plc (SAR) Top Compensated Officers